Daxor Corporation to Present at the Taglich Brothers 3rd Annual Small Cap Equity Conference; Senior Management Will Meet with Investors in New York City on May 2, 2006.NEW YORK -- Daxor Corporation (AMEX AMEX See: American Stock Exchange : DXR), a medical instrumentation and biotechnology company, today announced that Dr. Joseph Feldschuh, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Stephen Feldschuh, CFO See Chief Financial Officer. & VP of Operations, and John Reyes-Guerra, VP for Sales and Marketing, will be participating with 12 other companies in the exclusive Taglich Brothers Small Cap Equity Conference at 11:45 a.m. on May 2, 2006. The event will be held at Le Parker Meridien, New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , where institutional investors will obtain insight into the small-cap sector through direct interaction with company management teams. More information about the conference can be found at: www.taglich.com. About Daxor Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. Among nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer after using it on a trial basis are The Mayo Clinic, The Cleveland Clinic and New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the Medical Center For More Information Contact: For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh, 212-330-8515 (VP of Operations) stephen@daxor.com or Diane Meegan, 212-330-8512 (Investor Relations) dmeegan@daxor.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion